Peter H. O’Donnell

27.1k total citations · 6 hit papers
171 papers, 6.3k citations indexed

About

Peter H. O’Donnell is a scholar working on Surgery, Oncology and Pharmacology. According to data from OpenAlex, Peter H. O’Donnell has authored 171 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Surgery, 88 papers in Oncology and 35 papers in Pharmacology. Recurrent topics in Peter H. O’Donnell's work include Bladder and Urothelial Cancer Treatments (91 papers), Cancer Immunotherapy and Biomarkers (60 papers) and Urinary and Genital Oncology Studies (48 papers). Peter H. O’Donnell is often cited by papers focused on Bladder and Urothelial Cancer Treatments (91 papers), Cancer Immunotherapy and Biomarkers (60 papers) and Urinary and Genital Oncology Studies (48 papers). Peter H. O’Donnell collaborates with scholars based in United States, United Kingdom and Spain. Peter H. O’Donnell's co-authors include Noah M. Hahn, Arjun Vasant Balar, Joaquim Bellmunt, Elizabeth R. Plimack, M. Eileen Dolan, Petros Grivas, Rodolfo F. Perini, Daniel Castellano, Thomas Powles and Dean F. Bajorin and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Peter H. O’Donnell

157 papers receiving 6.2k citations

Hit Papers

First-line pembrolizumab in cisplatin-ineligible patients... 2016 2026 2019 2022 2017 2017 2016 2019 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    2017 939 citations Daniel Castellano, Peter H. O’Donnell et al. profile →
  2. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
    2017 664 citations Thomas Powles, Peter H. O’Donnell et al. profile →
  3. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
    2016 661 citations Peter H. O’Donnell et al. Journal of Clinical Oncology profile →
  4. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
    2019 435 citations Jonathan E. Rosenberg, Peter H. O’Donnell et al. Journal of Clinical Oncology profile →
  5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
    2021 175 citations Daniel P. Petrylak, Peter H. O’Donnell et al. profile →
  6. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
    2022 87 citations Mario E. Lacouture, Anisha B. Patel et al. The Oncologist profile →

Peers

Peter H. O’Donnell
Francesco Graziano Italy
Joong Bae Ahn South Korea
Angela Buonadonna Italy
Jan Stoehlmacher Germany
Mansoor Raza Mirza Denmark
Stéphane Culine France
Yves Chrétien France
Ashley E. Winkler United States
Benjamin Tan United States
Nirag Jhala United States
Francesco Graziano Italy
Peter H. O’Donnell
Citations per year, relative to Peter H. O’Donnell Peter H. O’Donnell (= 1×) peers Francesco Graziano

Countries citing papers authored by Peter H. O’Donnell

Since Specialization
Citations

This map shows the geographic impact of Peter H. O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter H. O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter H. O’Donnell more than expected).

Fields of papers citing papers by Peter H. O’Donnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter H. O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter H. O’Donnell. The network helps show where Peter H. O’Donnell may publish in the future.

Co-authorship network of co-authors of Peter H. O’Donnell

This figure shows the co-authorship network connecting the top 25 collaborators of Peter H. O’Donnell. A scholar is included among the top collaborators of Peter H. O’Donnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter H. O’Donnell. Peter H. O’Donnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Leary, Kevin J., Edith A. Nutescu, Tai C. Chen, et al.. (2025). Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clinical Pharmacology & Therapeutics. 119(1). 109–119. 1 indexed citations
2.
Raggi, Daniele, Filippo Pederzoli, Alberto Martini, et al.. (2025). HER2 and urothelial carcinoma: current understanding and future directions. Nature Reviews Urology. 23(2). 110–132. 1 indexed citations
3.
O’Leary, Kevin J., Edith A. Nutescu, Tai C. Chen, et al.. (2025). Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing. Clinical and Translational Science. 18(4). e70193–e70193. 1 indexed citations
4.
5.
6.
Saulsberry, Loren, et al.. (2025). A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information. Clinical Pharmacology & Therapeutics. 117(6). 1793–1802. 1 indexed citations
7.
Gao, Xin, Amita Patnaik, Nehal J. Lakhani, et al.. (2025). NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.. Journal of Clinical Oncology. 43(5_suppl). 2 indexed citations
8.
Vulsteke, Christof, Pongwut Danchaivijitr, Alejo Rodríguez‐Vida, et al.. (2025). LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. Annals of Oncology. 36. S1648–S1648. 1 indexed citations
9.
Desai, Kunal, Anthony V. Serritella, Walter M. Stadler, et al.. (2024). A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 30(11). 2384–2392. 3 indexed citations
10.
Huang, Daniel, Connor Lynch, Randy F. Sweis, et al.. (2024). Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clinical and Translational Radiation Oncology. 49. 100879–100879.
11.
Polley, Eric C., Peter H. O’Donnell, Frederick M. Howard, et al.. (2023). Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e12515–e12515. 1 indexed citations
12.
Rouhani, Sherin J., Jovian Yu, Daniel J. Olson, et al.. (2022). Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. Journal for ImmunoTherapy of Cancer. 10(6). e004766–e004766. 8 indexed citations
13.
Damrauer, Jeffrey S., Jeffrey A. Klomp, Mi Zhou, et al.. (2022). Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications. 13(1). 6658–6658. 27 indexed citations
14.
Lacouture, Mario E., Anisha B. Patel, Jonathan E. Rosenberg, & Peter H. O’Donnell. (2022). Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. The Oncologist. 27(3). e223–e232. 87 indexed citations breakdown →
15.
Reizine, Natalie, Keith Danahey, Ping Liu, et al.. (2021). Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. The Oncologist. 26(11). e2042–e2052. 12 indexed citations
16.
Apfelbaum, Jeffrey L., Sajid Shahul, Magdalena Anițescu, et al.. (2019). The ImPreSS Trial: Implementation of Point‐of‐Care Pharmacogenomic Decision Support in Perioperative Care. Clinical Pharmacology & Therapeutics. 106(6). 1179–1183. 13 indexed citations
17.
Danahey, Keith, et al.. (2017). Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. Journal of Biomedical Informatics. 75. 110–121. 36 indexed citations
18.
O’Donnell, Peter H., Theodore Karrison, Linda Janisch, et al.. (2015). Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research. 21(22). 5092–5099. 4 indexed citations
19.
Yap, Kai Lee, Kazuma Kiyotani, Kenji Tamura, et al.. (2014). Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival. Clinical Cancer Research. 20(24). 6605–6617. 64 indexed citations
20.
O’Donnell, Peter H., Keith Danahey, Michael Jacobs, et al.. (2014). Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 166(1). 68–75. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Graziano Breakdown of academic impact, for papers by Joong Bae Ahn Breakdown of academic impact, for papers by Angela Buonadonna Breakdown of academic impact, for papers by Jan Stoehlmacher Breakdown of academic impact, for papers by Mansoor Raza Mirza Breakdown of academic impact, for papers by Stéphane Culine Breakdown of academic impact, for papers by Yves Chrétien Breakdown of academic impact, for papers by Ashley E. Winkler Breakdown of academic impact, for papers by Benjamin Tan Breakdown of academic impact, for papers by Nirag Jhala
Rankless by CCL
2026